Company news

Evaxion A/S news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

October 23, 2026

Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

October 19, 2026

Decks

The 5 newest of 10 decks. Every deck is listed under its year.